Jennifer Kern
Family Health · Kingman, AZNPI 1992113906
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $529 and has fallen 81.0% since, to $101 in 2025.
Across 47 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$229
- Exact Sciences$142
- Lilly USA, LLC$138
- Novo Nordisk$116
- Amgen$104
- Boehringer Ingelheim$89
- plus $167 from 8 others
What the payments were for
- Food & beverage$96598%
- Education$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 6 | $229 |
| Exact Sciences | 8 | $142 |
| Lilly USA, LLC | 8 | $138 |
| Novo Nordisk | 7 | $116 |
| Amgen | 7 | $104 |
| Boehringer Ingelheim | 1 | $89 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Bayer | 2 | $31 |
| Galderma Laboratories, L.p. | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Merz North America, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$124
How this compares
Too few family health providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $102,142 |
| MounjaroTirzepatide | 49 | $88,038 |
| JardianceEmpagliflozin | 44 | $59,316 |
| EliquisApixaban | 32 | $48,162 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $25,239 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $16,917 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $8,955 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $8,211 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $6,939 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $5,505 |
| TradjentaLinagliptin | 11 | $5,326 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 112 | $5,268 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $4,071 |
| Levothyroxine Sodium | 455 | $3,809 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $3,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $116 | $102,14261 claims |
| Lilly USA, LLCMounjaro | $138 | $88,03849 claims |
| Boehringer IngelheimJardiance, Tradjenta | $89 | $64,64255 claims |
| PfizerEliquis | $14 | $48,16232 claims |
| AstraZenecaSymbicort | $19 | $6,93912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family health providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other family health in Kingman
- Larissa FloresPhoenix$3K
- Rodrigo CidBullhead City$3K
- Karen Runke PorcelloScottsdale$2K
- Cheryl ParkerTucson$1K
- Shawn SiqueirosTucson$510
- Sandra Barcelo-AdairSedona$276
- Jeff WaknitzSurprise$82
- Stewart LewisTucson$47
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.